newsroom.regeneron.comInvestor Relations | Regeneron Pharmaceuticals Inc.
newsroom.regeneron.com Profile
Newsroom.regeneron.com is a subdomain of regeneron.com,
which was created on 1997-07-10,making it 27 years ago.
It has several subdomains, such as clinicaltrials.regeneron.com
investor.regeneron.com , among others.
Description：The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial...
Discover newsroom.regeneron.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
newsroom.regeneron.com Information
| HomePage size: 97.251 KB |
| Page Load Time: 0.153693 Seconds |
| Website IP Address: 184.50.88.74 |
newsroom.regeneron.com Similar Website
| Masonite International Corp. - Investor Relations - Investor Relations |
| Investor Relations | Regeneron Pharmaceuticals Inc. |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Universal Technical Institute's Investor Relations - UTI Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Meridian Bank Investor Relations - Meridian Bank Investor Relations |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations |
| Walmart Investor Relations - Investor Relations |
newsroom.regeneron.com PopUrls
| 0001104659-24-008807 | 8-K | iXBRL Viewer https://newsroom.regeneron.com/node/29136/ixbrl-viewer |
| 0001104659-23-045897 | 8-K | iXBRL Viewer https://newsroom.regeneron.com/node/27921/ixbrl-viewer |
| 0001804220-21-000023 | 8-K | iXBRL Viewer https://newsroom.regeneron.com/node/25401/ixbrl-viewer |
| 8-K | iXBRL Viewer | Regeneron Pharmaceuticals INC https://newsroom.regeneron.com/node/24701/ixbrl-viewer |
| DEF 14A | iXBRL Viewer | Regeneron Pharmaceuticals INC https://newsroom.regeneron.com/node/27986/ixbrl-viewer |
| 0001104659-22-002403 | 8-K | iXBRL Viewer https://newsroom.regeneron.com/node/26201/ixbrl-viewer |
| 8-K | XBRL Viewer | Regeneron Pharmaceuticals INC https://newsroom.regeneron.com/node/27046/xbrl-viewer |
| 8-K | iXBRL Viewer | Regeneron Pharmaceuticals INC https://newsroom.regeneron.com/node/24186/ixbrl-viewer |
| 0001104659-23-099351 | 8-K/A | iXBRL Viewer https://newsroom.regeneron.com/node/28451/ixbrl-viewer |
| 0001804220-23-000029 | 8-K | iXBRL Viewer https://newsroom.regeneron.com/node/28661/ixbrl-viewer |
newsroom.regeneron.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1600075723" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Mon, 14 Sep 2020 09:28:43 GMT |
| Link: http://investor.regeneron.com/; rel="shortlink", https://newsroom.regeneron.com/investor-relations/; rel="canonical", https://newsroom.regeneron.com/investor-relations; rel="alternate"; hreflang="en", https://newsroom.regeneron.com/investor-relations; rel="revision", https://newsroom.regeneron.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Request-ID: v-aea0f322-f66c-11ea-8303-bfd23c5f51a6 |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 15925 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Mon, 14 Sep 2020 09:28:44 GMT |
| Date: Mon, 14 Sep 2020 09:28:44 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
| Strict-Transport-Security: max-age=15768000 ; preload |
newsroom.regeneron.com Meta Info
| charset="utf-8"/ |
| content="Regeneron Pharmaceuticals Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="https://newsroom.regeneron.com/investor-relations" property="og:url"/ |
| content="Investor Relations | Regeneron Pharmaceuticals Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
newsroom.regeneron.com Ip Information
| Ip Country: United States |
| City Name: San Jose |
| Latitude: 37.1835 |
| Longitude: -121.7714 |
newsroom.regeneron.com Html To Plain Text
Scientists Patients Medical Professionals Investors & Media Careers About Leadership Perspectives History Collaborations Industrial Operations Locations Science Pipeline Research Areas Antibodies Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST® ( rilonacept ) INJECTION DUPIXENT® ( dupilumab ) INJECTION EYLEA® ( aflibercept ) INJECTION KEVZARA® ( sarilumab ) INJECTION LIBTAYO® ( cemiplimab-rwlc) INJECTION PRALUENT® ( alirocumab ) INJECTION Responsibility Improving Lives Integrity & Excellence Sustainable Communities Regeneron STS & ISEF Transparancy & Policies Grants & Funding Investors &Media Careers Scientists Patients Medical Professionals Contact Us Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. Read on Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health. Read on Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body’s most complex mysteries. Read on To achieve our mission to repeatedly bring important new medicines to patients with serious diseases, we remain committed to running our business responsibly and operating with the highest standards of integrity. This commitment underscores our philosophy of ‘doing well by doing good,’ every day. Read on Investor Relations About Leadership Perspectives History Collaborations Industrial Operations Locations Science Pipeline Research Areas Antibodies Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc) INJECTION PRALUENT® ( alirocumab ) Injection Responsibility Improving Lives Integrity & Excellence Sustainable Communities Regeneron STS & ISEF Transparancy & Policies Grants & Funding Investors & Media News Events & Presentations Stock Information Financial Information Corporate Governance FAQs Careers Scientists Patients Medical Professionals Contact Us INVESTORS & MEDIA INVESTORS & MEDIA Investor Relations News Events Stock Information Financial Information Corporate Governance FAQs We are a leading science and technology company that delivers life-transforming medicines for serious diseases. Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases. In addition to our medicines, our innovations include the VelociSuite ® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good. Investor Relations High Low Volume Market Cap 09/14/20 5:28 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. 3 mo. 6 mo. 1 yr. Stock information Financial information 3 mo. 6 mo. 1 yr. Stock information Financial information NEWSROOM Sep 14 FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis Read on Sep 08 Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma Read on EVENTS Events Cantor Fitzgerald Virtual Global Healthcare Conference Sep 15 10:00 AM EDT Sep 15, 2020 | 10:00 AM EDT Listen to webcast Remind me: Add to Outlook Add to Google Calendar Morgan Stanley 18th Annual Global Healthcare Conference Sep 14 9:00 AM EDT Sep 14, 2020 | 9:00 AM EDT Listen to webcast Remind me: Add to Outlook Add to Google Calendar Events & Presentations Investor Relations High Low Volume Market Cap 09/14/20 5:28 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. 3 mo. 6 mo. 1 yr. Stock information Financial information Investor Relations 914.847.7741 invest@regeneron.com Media Relations media@regeneron.com Investor email alerts Download Center Add Files 2020 Proxy Statement 5.8 MB Add Files 2019 Annual Report 7.1 MB Add Files 2019 Responsibility Report 15.5 MB Add Files 2019 Form 10-K 2.5 MB Add Files Senior Management Biographies 3.3 MB Add Files Corporate Fact Sheet 2 MB Add Files Regeneron Genetics Center Backgrounder 1.9 MB Investor Relations 914.847.7741 invest@regeneron.com Media Relations media@regeneron.com Investor email alerts Email Alerts Email Alerts RSS RSS Print Print Share Share Search Search Facebook LinkedIn Twitter RSS About Leadership Perspectives History Collaborations Industrial Operations Locations Science Pipeline Research Areas Antibodies Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc ) Injection PRALUENT® ( alirocumab ) Injection Responsibility Improving Lives Integrity & Excellence Sustainable Communities Regeneron STS & ISEF Transparancy & Policies Grants & Funding Investors & Media News Events & Presentations Stock Information Financial Information Corporate Governance FAQs Careers Scientists Patients Medical Professionals Contact Us Terms of Use Privacy Policy Social Media Terms of Engagement Contact Us CAREERS Join our team and help turn science into life-changing medicine. Column 1 Investors & Media News Events & Presentations Stock Information Financial Information Corporate Governance FAQs Patients Medical Professionals Scientists Column 2 About Leadership Perspectives History Collaborations Industrial Operations Locations Science Pipeline Research Areas Antibodies Technology Regeneron Genetics Center Scientific Publications Column 3 Medicines ARCALYST® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc ) Injection PRALUENT® ( alirocumab ) Injection Responsibility Improving Lives Integrity & Excellence Sustainable Communities Regeneron STS & ISEF Transparancy & Policies Grants &...
newsroom.regeneron.com Whois
Domain Name: REGENERON.COM Registry Domain ID: 637549_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2023-05-10T06:42:45Z Creation Date: 1997-07-10T04:00:00Z Registry Expiry Date: 2028-07-09T04:00:00Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS11.WORLDNIC.COM Name Server: NS12.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T14:08:23Z <<<